Endocrinology (all articles)
M-A | SGLT2 inhibitors reduce the risk of kidney disease progression and AKI, irrespective of diabetes status.
11 Nov, 2022 | 14:04h | UTCCommentaries:
Meta-analysis backs SGLT2 inhibitors for kidney disease – medwire News
EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD – TCTMD
Commentary on Twitter
Our SGLT2 Trialists Consortium meta-analysis *the largest ever* in @TheLancet https://t.co/YlWkRQTDAW
Definitive evidence that SGLT2i ⬇️:
– Kidney failure
– AKI
– CV death
– All-cause deathRegardless of diabetes
Led by @NatalieStaplin @RichardHaynes3 @willkidney #AHA22 pic.twitter.com/uAX15mD9XY
— Brendon Neuen (@brendonneuen) November 6, 2022
Under a Creative Commons Attribution (CC BY 4.0) License
M-A | Head-to-head trials comparing sulfonylureas and low hypoglycemic risk antidiabetic drugs.
11 Nov, 2022 | 13:38h | UTC
Cohort Study | Study shows subclinical Hyperthyroidism is linked to an increased risk of fractures.
10 Nov, 2022 | 14:08h | UTCAssociation Between Subclinical Thyroid Dysfunction and Fracture Risk – JAMA Network Open
Commentary: Does Subclinical Hyperthyroidism Raise Fracture Risk? – Medscape (free registration required)
Commentary on Twitter
Subclinical hyperthyroidism may be an independent risk factor associated with fracture, highlighting a potential role for more aggressive screening and monitoring to prevent bone mineral disease. #OAReasearch https://t.co/LQVjaNU1zM
— JAMA Network Open (@JAMANetworkOpen) November 8, 2022
Cohort Study | Association of hormone therapy with depression during menopause.
9 Nov, 2022 | 12:17h | UTCCommentaries:
Expert reaction to study looking at HRT and depression during the menopause – Science Media Centre
Commentary on Twitter
Systemic hormone therapy (HT) before and during menopause is associated with higher risk of depression, especially in the years immediately after initiation; locally administered HT is associated with lower risk of depression for women ≥54 years. https://t.co/8k44K8SVtp
— JAMA Network Open (@JAMANetworkOpen) November 1, 2022
Canadian guideline for the prevention and management of cardiovascular disease in primary care.
8 Nov, 2022 | 12:37h | UTCNews Release: New one-stop guideline for cardiovascular health in Canada – Canadian Medical Association Journal
NICE Guideline | Obesity: identification, assessment and management.
8 Nov, 2022 | 12:35h | UTCRelated:
ASMBS Guidelines | Indications for metabolic and bariatric surgery.
AGA clinical practice guideline on pharmacological interventions for adults with obesity.
Guideline | Preventing obesity in midlife women.
Phase 2 RCT | Small interfering RNA to reduce Lipoprotein(a) in cardiovascular disease.
8 Nov, 2022 | 12:30h | UTCSmall Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Lipoprotein(a) is similar to LDL cholesterol but contains apolipoprotein(a). A trial tested the effects of an oligonucleotide drug targeting apo(a) mRNA on lipoprotein(a) concentrations in patients with CVD. #AHA22 https://t.co/eLgnrnTm5D pic.twitter.com/QmNUcxeJwX
— NEJM (@NEJM) November 6, 2022
RCT | Triglyceride lowering with Pemafibrate fails to reduce CVD risk in patients with Type 2 DM and hypertriglyceridemia.
7 Nov, 2022 | 12:54h | UTCTriglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk – New England Journal of Medicine (link to abstract – $ for full-text)
News Releases:
Commentaries:
Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT – TCTMD
Commentary on Twitter
In a randomized trial, the incidence of cardiovascular events was not lower in patients with diabetes, HTG, and low HDL cholesterol levels who received pemafibrate, although TG, VLDL cholesterol, remnant cholesterol, and Apo C-III levels decreased. #AHA22 https://t.co/bNtIAwWTX0 pic.twitter.com/yWaTWarlsv
— NEJM (@NEJM) November 5, 2022
RCT | Efficacy of a digital behavioral therapeutic application to improve glycemic control in adults with Type 2 DM.
7 Nov, 2022 | 12:33h | UTCCommentary: Smartphone-delivered CBT improves glycemic control in people with type 2 diabetes – medwire News
Crossover RCT | Efficacy of low-dose Empagliflozin as an adjunct to hybrid closed-loop insulin therapy in adults with Type 1 DM.
7 Nov, 2022 | 12:24h | UTCLow-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial – Diabetes Care (link to abstract – $ for full-text)
RCT | Once-weekly Semaglutide effective for weight loss in adolescents with obesity.
4 Nov, 2022 | 13:59h | UTCOnce-Weekly Semaglutide in Adolescents with Obesity – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
STEP TEENS: High-dose semaglutide weight loss benefits shown in adolescents – medwire News
Trial Shows Weight-Loss Drug Works in Teens – HealthDay
Commentary on Twitter
In this trial, adolescents with obesity assigned to weekly subcutaneous semaglutide plus lifestyle intervention had a greater reduction in BMI than those who received lifestyle intervention alone. https://t.co/yiFseP38xa pic.twitter.com/uRqkFfon1s
— NEJM (@NEJM) November 2, 2022
USPSTF Statement | Hormone therapy is not recommended for the prevention of chronic conditions in postmenopausal women.
3 Nov, 2022 | 14:19h | UTCEditorial: Menopausal Hormone Therapy for Prevention of Chronic Conditions: When Is Enough, Enough? – JAMA
JAMA Patient Page: Menopausal Hormone Therapy for Prevention of Chronic Conditions
Author Interview: USPSTF Recommendation: Hormone Therapy for Prevention of Postmenopausal Chronic Conditions – JAMA
Commentary: USPSTF: Hormone Therapy Not Advised for Primary Prevention of Chronic Conditions – HealthDay
Study suggests a personalized frequency of urinary albumin screening may be best for patients with Type 1 Diabetes.
3 Nov, 2022 | 13:46h | UTCOptimal Frequency of Urinary Albumin Screening in Type 1 Diabetes – Diabetes Care (link to abstract – $ for full-text)
Development, validation and clinical utility of a risk prediction model for adverse pregnancy outcomes in gestational diabetes.
3 Nov, 2022 | 13:45h | UTC
Commentary on Twitter (thread – click for more)
🧵PeRSonal GDM is a modelling tool that predicts if women with gestational diabetes could have ⬆️ risk of adverse pregnancy outcomes. It's being tested in other groups & developed as an online clinical calculator. New work by @DrShamilCooray @HelenaTeede & team in @eClinicalMed pic.twitter.com/tIyM4KHlre
— MCHRI (@MCHRImonash) September 5, 2022
M-A | Association of SGLT2 inhibitors with cardiovascular outcomes and safety events.
1 Nov, 2022 | 11:56h | UTC
M-A of RCT | Comparison of low carbohydrate vs. low fat diets in Type 2 DM.
31 Oct, 2022 | 13:55h | UTC
RCT | Effects of a low-carbohydrate dietary intervention on hemoglobin A1c.
31 Oct, 2022 | 13:54h | UTCSee also: Visual Abstract
News Release: At risk for diabetes? Cut the carbs, says new study – Tulane University
Commentaries:
Low-Carb Diet Promising for Lowering Blood Sugar in Prediabetes – TCTMD
Cohort Study | Risk factors of pancreatic cancer in patients with Type 2 DM.
31 Oct, 2022 | 13:47h | UTC
Guidance for the diagnosis and treatment of hypolipidemia disorders.
28 Oct, 2022 | 13:19h | UTCGuidance for the diagnosis and treatment of hypolipidemia disorders – Journal of Clinical Lipidology
2022 ETA Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma.
27 Oct, 2022 | 12:33h | UTCCommentary: New EU Guidelines: Individualize Care for Thyroid Cancer in Kids – Medscape (free registration required)
Review | Hypercalcemia.
26 Oct, 2022 | 14:37h | UTCHypercalcemia: A Review – JAMA (free for a limited period)
Author Interview: Hypercalcemia—A Review – JAMA
M-A | Age, sex, race, BMI, and duration of type 2 DM differences in cardiovascular outcomes with glucose lowering drugs.
26 Oct, 2022 | 14:32h | UTCCommentary: Meta-analysis may guide optimal type 2 diabetes glucose-lowering agent for MACE protection – medwire News
ASMBS Guidelines | Indications for metabolic and bariatric surgery.
24 Oct, 2022 | 14:17h | UTCNews Release: After 30 years — new guidelines for weight-loss surgery – American Society for Metabolic and Bariatric Surgery
Commentary: New guidelines expand eligibility for weight loss surgery. Will insurance coverage follow? – USA Today
Commentary on Twitter
✴️ Updated Indictions of #BariatricSurgery for treating #obesity by @ASMBS @IfsoSecretariat https://t.co/TrTcCEu0q1 pic.twitter.com/c5s15FmXpp
— Ali Aminian (@Ali_Aminian_MD) October 21, 2022
KDIGO 2022 Clinical practice guideline for diabetes management in chronic kidney disease.
24 Oct, 2022 | 14:16h | UTCRelated: ADA/KDIGO Consensus Report | Diabetes management in chronic kidney disease.
AGA clinical practice guideline on pharmacological interventions for adults with obesity.
21 Oct, 2022 | 13:06h | UTC